Immix Biopharma, Inc. is a biotechnology company focused on developing innovative therapies for a range of medical conditions, particularly in the area of immuno-oncology
The company aims to harness the body's immune system to fight cancer and other diseases by creating advanced treatment options that target specific disease mechanisms. Immix Biopharma is dedicated to conducting rigorous research and clinical trials to bring novel therapeutic solutions from the lab to the market, ultimately improving patient outcomes and enhancing quality of life.
Shares of Humana Inc. (NYSEHUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.
Immix Biopharma Inc (NASDAQIMMX) announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 study of its NXC-201, an autologous, BCMA-targeted chimeric antigen receptor T
Immix Biopharma Inc's (NASDAQIMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for relapsed or refractory multiple myel
Gainers SeqLL Inc. (NASDAQSQL) shares surged 61.1% to $0.54 in pre-market trading after dropping 14% on Friday. SeqLL recently posted a wider first-quarter loss.
Immix Biopharma Inc (NASDAQIMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd NYSE: BGNENYSEBGNE)
Gainers Evelo Biosciences, Inc. (NASDAQEVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its EDP1815 Phase 2 trial, in which the primary endpoint was not met.
